Investors should take a close look at two stocks with strong momentum characteristics and a buy rank.
ADMA Biologics, Inc. ADMA is a biopharmaceutical company with a Zacks Rank #1. The Zacks Consensus Estimate for its current year earnings has surged 33.3% over the last 60 days.
ADMA Biologics Inc: Momentum in Action
ADMA Biologics Inc price-consensus-chart | ADMA Biologics Inc Quote
ADMA’s shares have outperformed the S&P 500, gaining 55.5% over the last three months. The company boasts a Momentum Score of A.
ADMA Biologics Inc: Riding the Price Wave
ADMA Biologics Inc price | ADMA Biologics Inc Quote
Arcutis Biotherapeutics, Inc. ARQT is another biopharmaceutical company with a Zacks Rank #1. It has seen the Zacks Consensus Estimate for its current year earnings rise by 10.4% over the last 60 days.
Arcutis Biotherapeutics Inc: Surging Ahead
Arcutis Biotherapeutics, Inc. price-consensus-chart | Arcutis Biotherapeutics, Inc. Quote
Arcutis has outperformed the S&P 500 by gaining 101% over the last month. With a Momentum Score of A, the company is clearly on the fast track.
Arcutis Biotherapeutics Inc: Navigating the Market Currents
Arcutis Biotherapeutics, Inc. price | Arcutis Biotherapeutics, Inc. Quote
For a comprehensive list of high-ranked stocks, view the full list here
Dig deeper into the Momentum score methodology here.
(We are reissuing this article to correct a mistake. The original article, issued on January 11, 2024, should no longer be relied upon.)
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution accelerates, investors have a chance to ride a seismic wave of opportunity. The demand for lithium batteries, predicted to soar by an astounding 889%, presents a tantalizing prospect for potential investors.
Access the latest FREE report highlighting 5 EV battery stocks set to skyrocket.
Detailed Stock Analysis Report for ADMA Biologics Inc (ADMA)
Detailed Stock Analysis Report for Arcutis Biotherapeutics, Inc. (ARQT)
For the full article, visit Zacks.com here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
